Skip to content

Debt Repayments at other companies

Eli Lilly logo
Eli LillyLLY
$750M
Arrowhead Research logo
Arrowhead ResearchARWR
$17.83M-88.2%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$0-100%

Other financials

Income statement

See full
Revenue$267.9M-40.7%
Gross profit$265.2M-40.8%
Operating income-$102.3M-173%
Net income-$114.6M-193%
EPS (diluted)-$0.69-199%

Balance sheet

See full
Cash & equivalents$350.1M+17.7%
Total debt$262.5M-67.0%
Total equity$439.7M-30.4%
Total assets$3.0B+0.3%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$16.1M+30.7%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$9.25B+38.4%
Enterprise value$9.16B+27.5%
P/S10.6×+3.5×

Profitability

See full
Gross margin98.2%-0.7pp
Operating margin-68%-234pp
Net margin-64.7%-299pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-105.5%+336pp
Debt / equity0.6×-0.7×
Current ratio7.9×+5.0×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RepaymentsOfConvertibleDebt.

The official record: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ionis Pharmaceuticals's debt repayments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ionis Pharmaceuticals's debt repayments?
Ionis Pharmaceuticals (IONS) reported debt repayments of $0 in Q4 2025.
How has Ionis Pharmaceuticals's debt repayments changed year-over-year?
Ionis Pharmaceuticals's debt repayments decreased by 100.0% year-over-year, from $44.5M to $0.
What does debt repayments mean?
Cash used to repay or retire outstanding debt obligations, including scheduled maturities and early redemptions.